Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Lifeward Ltd. - Ordinary Shares (LFWD)
Company Research
Source: GlobeNewswire
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company has received CE mark approval for the ReWalk 7 Personal Exoskeleton, clearing it for commercial sale in Europe. The seventh generation of the ReWalk, which includes innovative new and enhanced features such as cloud connectivity, push-button control, customizable walking speeds, and seamless activation of stairs and curbs, will now be available to European customers, who currently represent approximately 40% of Lifeward’s exoskeleton sales. The majority of these sales are generated through Lifeward GmbH, where the process of reimbursement for personal exoskeletons has been broadly established for individuals in Germany. “The ReWalk 7 represents a major advancement in personal exoskeleton technol
Show less
Read more
Impact Snapshot
Event Time:
LFWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LFWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LFWD alerts
High impacting Lifeward Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LFWD
News
- Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization ApprovalGlobeNewswire
- Lifeward (NASDAQ:LFWD) had its price target lowered by analysts at HC Wainwright from $13.00 to $4.50. They now have a "buy" rating on the stock.MarketBeat
- UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal ExoskeletonGlobeNewswire
- Lifeward Ltd. Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- Lifeward to Report Third Quarter Financial Results on November 14, 2025GlobeNewswire
LFWD
Earnings
- 11/14/25 - Miss
LFWD
Sec Filings
- 12/1/25 - Form DEF
- 11/21/25 - Form PRE
- 11/14/25 - Form 10-Q
- LFWD's page on the SEC website